Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis

NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.

The release as fetched from its publisher. akaritx.com ↗